Analyzing Evolus (NASDAQ:EOLS) & Nutriband (NASDAQ:NTRB)

Evolus (NASDAQ:EOLS) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Evolus and Nutriband”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18 million	1.71	-$51.64 million	($0.52)	-14.79
Nutriband	$2.04 million	43.87	-$8.23 million	($0.53)	-13.89

Nutriband has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

90.7% of Evolus shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 5.0% of Evolus shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Evolus has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Nutriband has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.

Profitability

This table compares Evolus and Nutriband’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evolus	-10.85%	N/A	-13.00%
Nutriband	-430.35%	-109.07%	-95.54%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Evolus and Nutriband, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1	1	4	0	2.50
Nutriband	1	1	0	0	1.50

Evolus currently has a consensus target price of $14.50, indicating a potential upside of 88.56%. Given Evolus’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Evolus is more favorable than Nutriband.

Summary

Evolus beats Nutriband on 9 of the 14 factors compared between the two stocks.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.